The estimated Net Worth of Joseph S Mc Cracken is at least $727 Tisíc dollars as of 15 March 2021. Joseph Cracken owns over 68,965 units of Savara Inc stock worth over $727,216 and over the last 9 years he sold SVRA stock worth over $0. In addition, he makes $0 as Independent Director at Savara Inc.
Joseph has made over 13 trades of the Savara Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he bought 68,965 units of SVRA stock worth $99,999 on 15 March 2021.
The largest trade he's ever made was buying 68,965 units of Savara Inc stock on 15 March 2021 worth over $99,999. On average, Joseph trades about 5,884 units every 60 days since 2016. As of 15 March 2021 he still owns at least 168,337 units of Savara Inc stock.
You can see the complete history of Joseph Cracken stock trades at the bottom of the page.
Dr. Joseph S. McCracken Ph.D. serves as Independent Director of the Company. Dr. McCracken currently advises biopharmaceutical companies on the design and implementation of corporate strategy and business development initiatives. Dr. McCracken also serves on the board of Kindred Biosciences, Inc. (NASDAQ: KIN) and Lumos Pharma, Inc. (NASDAQ: LUMO), as well as the boards of privately held Alkahest, Inc., Modalis Therapeutics, Inc., Regimmune Inc., and Neuropore Therapies, Inc. From July 2011 to September 2013, Dr. McCracken was Vice President and Global Head of Business Development & Licensing for Roche Pharma, a research-focused healthcare company, where he was responsible for Roche Pharma’s global in-licensing and out-licensing activities. From October 2009 until July 2011, he was General Manager, Roche Pharma Japan & Asia Regional Head, Roche Partnering. Prior to joining Roche Pharma, Dr. McCracken held the position of Vice President, Business Development at Genentech for more than 9 years, and previously held similar positions at Aventis Pharma and Rhone-Poulenc Rorer. Dr. McCracken holds a Bachelor of Science in Microbiology, a Master of Science in Pharmacology and a Doctorate of Veterinary Medicine from The Ohio State University. McCracken’s extensive experience in the biotechnology and pharmaceutical industries qualifies him to serve on the Board of Directors.
Joseph McCracken is 66, he's been the Independent Director of Savara Inc since 2017. There are 1 older and 10 younger executives at Savara Inc. The oldest executive at Savara Inc is Richard Hawkins, 71, who is the Independent Director.
Joseph's mailing address filed with the SEC is ONE SUMMIT SQUARE,, 1717 LANGHORNE NEWTOWN ROAD, SUITE 300, LANGHORNE, PA, 19047.
Over the last 7 years, insiders at Savara Inc have traded over $2,203,958 worth of Savara Inc stock and bought 6,103,761 units worth $15,290,245 . The most active insiders traders include Forest Baskett, Scott D Sandell a Anthony A. Jr. Florence. On average, Savara Inc executives and independent directors trade stock every 29 days with the average trade being worth of $348,922. The most recent stock trade was executed by Matthew Pauls on 28 December 2023, trading 84,000 units of SVRA stock currently worth $395,640.
savara pharmaceuticals is an emerging specialty pharmaceutical company developing innovative pulmonary drugs for the treatment of serious and life-threatening conditions. the company’s lead product, aerovanc is the first dry powder inhaled antibiotic for the treatment of methicillin-resistant staphylococcus aureus (mrsa) infection in patients with cystic fibrosis (cf). for more information, please see savara’s website at www.savarapharma.com or www.aerovanc.com
Savara Inc executives and other stock owners filed with the SEC include: